4.8 Article

Essential role for a novel population of binucleated mammary epithelial cells in lactation

期刊

NATURE COMMUNICATIONS
卷 7, 期 -, 页码 -

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/ncomms11400

关键词

-

资金

  1. Victorian State Government
  2. Australian National Health and Medical Research Council (NHMRC) [1016701, 1085191, 1086727]
  3. NHMRC IRIISS
  4. Victorian State Government through Victorian Cancer Agency
  5. Australian Cancer Research Foundation
  6. National Breast Cancer Foundation (NBCF)/Cure Cancer Australia Fellowship
  7. NHMRC [1078730]
  8. [1037230]
  9. National Health and Medical Research Council of Australia [1086727, 1085191, 1078730] Funding Source: NHMRC

向作者/读者索取更多资源

The mammary gland represents a unique tissue to study organogenesis as it predominantly develops in the post-natal animal and undergoes dramatic morphogenetic changes during puberty and the reproductive cycle. The physiological function of the mammary gland is to produce milk to sustain the newborn. Here we view the lactating gland through three-dimensional confocal imaging of intact tissue. We observed that the majority of secretory alveolar cells are binucleated. These cells first arise in very late pregnancy due to failure of cytokinesis and are larger than mononucleated cells. Augmented expression of Aurora kinase-A and Polo-like kinase-1 at the lactogenic switch likely mediates the formation of binucleated cells. Our findings demonstrate an important physiological role for polyploid mammary epithelial cells in lactation, and based on their presence in five different species, suggest that binucleated cells evolved to maximize milk production and promote the survival of offspring across all mammalian species.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

PALVEN: phase 1b trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer

Christine Muttiah, James R. Whittle, Catherine Oakman, Geoffrey J. Lindeman

Summary: The current standard treatment for estrogen receptor-positive, HER2-negative metastatic breast cancer is endocrine therapy with a CDK4/6 inhibitor. This study aims to investigate the potential benefits of adding the BCL2 inhibitor venetoclax to the treatment regimen. A phase 1 trial will be conducted to determine the optimal dosages for combination therapy.

FUTURE ONCOLOGY (2022)

Article Oncology

In vivo genome-editing screen identifies tumor suppressor genes that cooperate with Trp53 loss during mammary tumorigenesis

Luuk Heitink, James R. Whittle, Francois Vaillant, Bianca D. Capaldo, Johanna F. Dekkers, Caleb A. Dawson, Michael J. G. Milevskiy, Elliot Surgenor, Minhsuang Tsai, Huei-Rong Chen, Michael Christie, Yunshun Chen, Gordon K. Smyth, Marco J. Herold, Andreas Strasser, Geoffrey J. Lindeman, Jane E. Visvader

Summary: Breast cancer is a heterogeneous disease with multiple histological and molecular subtypes. This study describes a pipeline for identifying and validating tumor suppressor genes in breast cancer. Through in vivo and ex vivo experiments, several tumor suppressor genes were identified. The mutations in these genes were shown to accelerate tumor development in breast cancer.

MOLECULAR ONCOLOGY (2022)

Article Immunology

A diverse fibroblastic stromal cell landscape in the spleen directs tissue homeostasis and immunity

Yannick O. Alexandre, Dominik Schienstock, Hyun Jae Lee, Luke C. Gandolfo, Cameron G. Williams, Sapna Devi, Bhupinder Pal, Joanna R. Groom, Wang Cao, Susan N. Christo, Claire L. Gordon, Graham Starkey, Rohit D'Costa, Laura K. Mackay, Ashraful Haque, Burkhard Ludewig, Gabrielle T. Belz, Scott N. Mueller

Summary: This article provides a comprehensive understanding of the cellular and molecular characteristics of fibroblastic stromal cells in the spleen, revealing their significance and diversity in maintaining tissue homeostasis and orchestrating immune responses.

SCIENCE IMMUNOLOGY (2022)

Article Oncology

VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors - Efficacy, Safety, and Biomarker Results

Geoffrey J. Lindeman, Tharu M. Fernando, Rebecca Bowen, Katarzyna J. Jerzak, Xinni Song, Thomas Decker, Frances Boyle, Steve McCune, Anne Armstrong, Catherine Shannon, Gianfilippo Bertelli, Ching-Wei Chang, Rupal Desai, Kushagra Gupta, Timothy R. Wilson, Aulde Flechais, Aditya Bardia

Summary: The combination of venetoclax and fulvestrant did not show clinical utility in endocrine therapy-resistant, CDK4/6 inhibitor-refractory metastatic breast cancer, but suggested a possible increased dependence on BCLXL in this setting.

CLINICAL CANCER RESEARCH (2022)

Review Biochemistry & Molecular Biology

3D imaging for driving cancer discovery

Ravian L. van Ineveld, Esmee J. van Vliet, Ellen J. Wehrens, Maria Alieva, Anne C. Rios

Summary: This article introduces the importance and potential applications of 3D imaging in cancer research. 3D imaging provides more accurate information about the cellular composition and structure of cancer, and offers new strategies and methods for cancer treatment and patient diagnosis.

EMBO JOURNAL (2022)

Article Multidisciplinary Sciences

R code and downstream analysis objects for the scRNA-seq atlas of normal and tumorigenic human breast tissue

Yunshun Chen, Bhupinder Pal, Geoffrey J. Lindeman, Jane E. Visvader, Gordon K. Smyth

Summary: This article extends our understanding of the development mechanism of breast cancer by providing quality control thresholds, processed data objects, complete cell annotation, and R code for analysis of a large-scale single-cell RNA expression atlas.

SCIENTIFIC DATA (2022)

Article Hematology

Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells

Charis E. Teh, Hongke Peng, Meng-Xiao Luo, Tania Tan, Marie Trussart, Lauren J. Howson, Chong Chyn Chua, Christine Muttiah, Fiona Brown, Matthew E. Ritchie, Andrew H. Wei, Andrew W. Roberts, Vanessa L. Bryant, Mary Ann Anderson, Geoffrey J. Lindeman, David C. S. Huang, Rachel Thijssen, Daniel H. D. Gray

Summary: Venetoclax is effective for certain blood cancers, but relapse is common. Combining it with immunotherapies is promising, but its impact on normal immune cells is unclear. This study found minimal impact on T and NK cells, supporting the potential combination of Venetoclax with immunotherapies for better anti-tumor responses.

BLOOD ADVANCES (2023)

Review Biochemistry & Molecular Biology

Deciphering breast cancer: from biology to the clinic

Emma Nolan, Geoffrey J. Lindeman, Jane E. Visvader

Summary: Breast cancer is a major cause of cancer-related death in women due to its heterogeneity, metastasis, and resistance to treatment. Recent advances in genomics and transcriptomics have revealed distinct subtypes, molecular drivers, evolutionary patterns, and prognostic markers. Moreover, the integration of high-resolution single-cell and spatial technologies has revealed the significance of the breast cancer ecosystem and different cellular neighborhoods.
Article Medicine, General & Internal

Universal genetic testing for women with newly diagnosed breast cancer in the context of multidisciplinary team care

Dilanka L. De Silva, Lesley Stafford, Anita R. Skandarajah, Michelle Sinclair, Lisa Devereux, Kirsten Hogg, Maira Kentwell, Allan Park, Luxi Lal, Magnus Zethoven, Madawa W. Jayawardana, Fiona Chan, Phyllis N. Butow, Paul A. James, G. Bruce Mann, Ian G. Campbell, Geoffrey J. Lindeman

Summary: This study aimed to assess the feasibility of universal genetic testing for women with newly diagnosed breast cancer. The study found that 6.5% of participants had pathogenic germline variants, and 18 of them did not meet the current genetic testing eligibility guidelines. Clinical management was changed for 24 women after the identification of pathogenic variants. Acceptance of universal testing was high among both patients and clinicians.

MEDICAL JOURNAL OF AUSTRALIA (2023)

Article Multidisciplinary Sciences

Single-cell transcriptomics reveals immune suppression and cell states predictive of patient outcomes in rhabdomyosarcoma

Jeff DeMartino, Michael T. Meister, Lindy L. Visser, Mariel Brok, Marian J. A. Groot Koerkamp, Amber K. L. Wezenaar, Laura S. Hiemcke-Jiwa, Terezinha de Souza, Johannes H. M. Merks, Anne C. Rios, Frank C. P. Holstege, Thanasis Margaritis, Jarno Drost

Summary: This study explores the cellular differentiation states of paediatric rhabdomyosarcoma (RMS) using single-cell RNA sequencing analysis and identifies an immunosuppressive microenvironment and transcriptional programs predictive of patient outcomes. The research generates a transcriptomic atlas of RMS and reveals evidence of an immunosuppressive microenvironment in the RMS tumour niche. The study also highlights the potential of therapies targeting the immune microenvironment and suggests that assessing tumour differentiation states may enable a more refined risk stratification.

NATURE COMMUNICATIONS (2023)

Article Cell Biology

Three-dimensional genome architecture coordinates key regulators of lineage specification in mammary epithelial cells

Michael J. G. Milevskiy, Hannah D. Coughlan, Serena R. Kane, Timothy M. Johanson, Somayeh Kordafshari, Wing Fuk Chan, Minhsuang Tsai, Elliot Surgenor, Stephen Wilcox, Rhys S. Allan, Yunshun Chen, Geoffrey J. Lindeman, Gordon K. Smyth, Jane E. Visvader

Summary: This study provides a comprehensive analysis of the chromatin landscape of epithelial subsets in the mammary gland, revealing the contribution of 3D genome organization to gene regulation in the epithelium. The results demonstrate that lineage-specific genes exhibit lineage specificity through distal enhancers, while luminal-specific genes display promoter priming in basal cells. Chromatin interactions with super enhancers and polycomb silencer elements play a major role in the cell specificity of luminal progenitors.

CELL GENOMICS (2023)

Article Biochemistry & Molecular Biology

Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer

Shikhar Sharma, Chi-Yeh Chung, Sean Uryu, Jelena Petrovic, Joan Cao, Amanda Rickard, Nataliya Nady, Samantha Greasley, Eric Johnson, Oleg Brodsky, Showkhin Khan, Hui Wang, Zhenxiong Wang, Yong Zhang, Konstantinos Tsaparikos, Lei Chen, Anthony Mazurek, John Lapek, Pei-Pei Kung, Scott Sutton, Paul F. Richardson, Eric C. Greenwald, Shinji Yamazaki, Rhys Jones, Karen A. Maegley, Patrick Bingham, Hieu Lam, Alexandra E. Stupple, Aileen Kamal, Anderly Chueh, Anthony Cuzzupe, Benjamin J. Morrow, Bin Ren, Catalina Carrasco-Pozo, Chin Wee Tan, Dharmesh D. Bhuva, Elizabeth Allan, Elliot Surgenor, Francois Vaillant, Havva Pehlivanoglu, Hendrik Falk, James R. Whittle, Janet Newman, Joseph Cursons, Judy P. Doherty, Karen L. White, Laura Macpherson, Mark Devlin, Matthew L. Dennis, Meghan K. Hattarki, Melanie De Silva, Michelle A. Camerino, Miriam S. Butler, Olan Dolezal, Patricia Pilling, Richard Foitzik, Paul A. Stupple, H. Rachel Lagiakos, Scott R. Walker, Soroor Hediyeh-Zadeh, Stewart Nuttall, Sukhdeep Spall, Susan A. Charman, Theresa Connor, Thomas S. Peat, Vicky M. Avery, Ylva E. Bozikis, Yuqing Yang, Ming Zhang, Brendon J. Monahan, Anne K. Voss, Ian P. Street, Sarah-Jane Dawson, Mark A. Dawson, Geoffrey J. Lindeman, Melissa J. Davis, Jane E. Visvader, Thomas A. Paul

Summary: In this study, a highly potent, selective, and orally bioavailable KAT6A/KAT6B inhibitor CTx-648 was identified, which inhibits H3K23 acetylation and exhibits anti-tumor activity in ER+ breast cancer. The mechanism of action may involve the modulation of transcriptional and epigenetic profiles.

CELL CHEMICAL BIOLOGY (2023)

Review Oncology

Bridging live-cell imaging and next-generation cancer treatment

Maria Alieva, Amber K. L. Wezenaar, Ellen J. Wehrens, Anne C. Rios

Summary: Live-cell imaging provides a deeper understanding of cancer response to treatment by offering spatial, molecular, and morphological data over time. It has been applied to uncover tumour heterogeneity in treatment response and the mode of action of cancer-targeting drugs. The unique opportunity of time-lapse imaging in capturing the interactivity and motility of immunotherapies is also discussed. Recent technological advancements in multidimensional imaging and multi-omics data integration have allowed for the connection of single-cell dynamics to molecular phenotypes. These advancements significantly contribute to our understanding of tumour targeting and have implications for next-generation precision medicine.

NATURE REVIEWS CANCER (2023)

Article Oncology

Common variants in breast cancer risk loci predispose to distinct tumor subtypes

Thomas U. Ahearn, Haoyu Zhang, Kyriaki Michailidou, Roger L. Milne, Manjeet K. Bolla, Joe Dennis, Alison M. Dunning, Michael Lush, Qin Wang, Irene L. Andrulis, Hoda Anton-Culver, Volker Arndt, Kristan J. Aronson, Paul L. Auer, Annelie Augustinsson, Adinda Baten, Heiko Becher, Sabine Behrens, Javier Benitez, Marina Bermisheva, Carl Blomqvist, Stig E. Bojesen, Bernardo Bonanni, Anne-Lise Borresen-Dale, Hiltrud Brauch, Hermann Brenner, Angela Brooks-Wilson, Thomas Bruening, Barbara Burwinkel, Saundra S. Buys, Federico Canzian, Jose E. Castelao, Jenny Chang-Claude, Stephen J. Chanock, Georgia Chenevix-Trench, Christine L. Clarke, J. Margriet Collee, Angela Cox, Simon S. Cross, Kamila Czene, Mary B. Daly, Peter Devilee, Thilo Dork, Miriam Dwek, Diana M. Eccles, D. Gareth Evans, Peter A. Fasching, Jonine Figueroa, Giuseppe Floris, Manuela Gago-Dominguez, Susan M. Gapstur, Jose A. Garcia-Saenz, Mia M. Gaudet, Graham G. Giles, Mark S. Goldberg, Anna Gonzalez-Neira, Grethe I. Grenaker Alnaes, Mervi Grip, Pascal Guenel, Christopher A. Haiman, Per Hall, Ute Hamann, Elaine F. Harkness, Bernadette A. M. Heemskerk-Gerritsen, Bernd Holleczek, Antoinette Hollestelle, Maartje J. Hooning, Robert N. Hoover, John L. Hopper, Anthony Howell, Milena Jakimovska, Anna Jakubowska, Esther M. John, Michael E. Jones, Audrey Jung, Rudolf Kaaks, Saila Kauppila, Renske Keeman, Elza Khusnutdinova, Cari M. Kitahara, Yon-Dschun Ko, Stella Koutros, Vessela N. Kristensen, Ute Kruger, Katerina Kubelka-Sabit, Allison W. Kurian, Kyriacos Kyriacou, Diether Lambrechts, Derrick G. Lee, Annika Lindblom, Martha Linet, Jolanta Lissowska, Ana Llaneza, Wing-Yee Lo, Robert J. MacInnis, Arto Mannermaa, Mehdi Manoochehri, Sara Margolin, Maria Elena Martinez, Catriona McLean, Alfons Meindl, Usha Menon, Heli Nevanlinna, William G. Newman, Jesse Nodora, Kenneth Offit, Hakan Olsson, Nick Orr, Tjoung-Won Park-Simon, Alpa Patel, Julian Peto, Guillermo Pita, Dijana Plaseska-Karanfilska, Ross Prentice, Kevin Punie, Katri Pylkas, Paolo Radice, Gad Rennert, Atocha Romero, Thomas Ruediger, Emmanouil Saloustros, Sarah Sampson, Dale P. Sandler, Elinor J. Sawyer, Rita K. Schmutzler, Minouk J. Schoemaker, Ben Schottker, Mark E. Sherman, Xiao-Ou Shu, Snezhana Smichkoska, Melissa C. Southey, John J. Spinelli, Anthony J. Swerdlow, Rulla M. Tamimi, William J. Tapper, Jack A. Taylor, Lauren R. Teras, Mary Beth Terry, Diana Torres, Melissa A. Troester, Celine M. Vachon, Carolien H. M. van Deurzen, Elke M. van Veen, Philippe Wagner, Clarice R. Weinberg, Camilla Wendt, Jelle Wesseling, Robert Winqvist, Alicja Wolk, Xiaohong R. Yang, Wei Zheng, Fergus J. Couch, Jacques Simard, Peter Kraft, Douglas F. Easton, Paul D. P. Pharoah, Marjanka K. Schmidt, Montserrat Garcia-Closas, Nilanjan Chatterjee

Summary: This study identifies breast cancer susceptibility variants that are associated with tumor features and intrinsic molecular subtypes, providing insights for subtype-specific risk prediction.

BREAST CANCER RESEARCH (2022)

暂无数据